Skip to Content
Merck
  • The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24.

The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24.

Immunity (2020-07-17)
Wai Po Chong, Mary J Mattapallil, Kumarkrishna Raychaudhuri, So Jin Bing, Sihan Wu, Yajie Zhong, WeiWei Wang, Zilin Chen, Phyllis B Silver, Yingyos Jittayasothorn, Chi-Chao Chan, Jun Chen, Reiko Horai, Rachel R Caspi
ABSTRACT

Dysregulated Th17 cell responses underlie multiple inflammatory and autoimmune diseases, including autoimmune uveitis and its animal model, EAU. However, clinical trials targeting IL-17A in uveitis were not successful. Here, we report that Th17 cells were regulated by their own signature cytokine, IL-17A. Loss of IL-17A in autopathogenic Th17 cells did not reduce their pathogenicity and instead elevated their expression of the Th17 cytokines GM-CSF and IL-17F. Mechanistic in vitro studies revealed a Th17 cell-intrinsic autocrine loop triggered by binding of IL-17A to its receptor, leading to activation of the transcription factor NF-κB and induction of IL-24, which repressed the Th17 cytokine program. In vivo, IL-24 treatment ameliorated Th17-induced EAU, whereas silencing of IL-24 in Th17 cells enhanced disease. This regulatory pathway also operated in human Th17 cells. Thus, IL-17A limits pathogenicity of Th17 cells by inducing IL-24. These findings may explain the disappointing therapeutic effect of targeting IL-17A in uveitis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Freund′s Adjuvant, Complete, cell suspension
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Socs1
Sigma-Aldrich
Human IL24 / Interleukin-24 ELISA Kit
Sigma-Aldrich
MISSION® esiRNA, targeting human IL24